HUTCHMED (China) Ltd
HKEX:13
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
HK |
|
S
|
S4 Capital PLC
OTC:SCPPF
|
UK |
|
Philip Morris CR as
F:TBK
|
CZ |
|
T
|
Toyota Motor Corp
XMUN:TOM
|
JP |
Intrinsic Value
Is HUTCHMED (China) Ltd undervalued or overvalued?
See the intrinsic value estimate for HUTCHMED (China) Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
HUTCHMED (China) Ltd looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with HUTCHMED (China) Ltd’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What HUTCHMED (China) Does
HUTCHMED is a biopharmaceutical company that discovers and develops cancer medicines, especially targeted therapies and immunotherapies. It also works on treatments for immune and inflammatory diseases. The company’s main job is to take drug candidates from research into clinical testing and then turn the successful ones into approved medicines for patients.
- Headquarters
- Hong Kong HK
- Employees
- 1 796
- IPO date
- May 19, 2006
Earnings Waterfall
HUTCHMED (China) Ltd
The intrinsic value for HUTCHMED (China) Ltd (13) under the Base Case is hidden HKD.
Compared with the current market price of 21.44 HKD, the stock appears hidden.